No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy

Alexandra K. Walker; Christiana Kartsonaki; Elena Collantes; Judith Nicholson; Duncan C. Gilbert; Anne E. Kiltie

doi:10.1038/bjc.2017.188

No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy

Alexandra K. Walker, Christiana Kartsonaki, Elena Collantes, Judith Nicholson, Duncan C. Gilbert, Anne E. Kiltie^*

^*Corresponding author for this work

The Rowett Institute of Nutrition and Health

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background:The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers.Methods:Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease.Results:We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy.Conclusions:MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.

Original language	English
Pages (from-to)	322-325
Number of pages	4
Journal	British Journal of Cancer
Volume	117
Issue number	3
DOIs	https://doi.org/10.1038/bjc.2017.188
Publication status	Published - 25 Jul 2017

Bibliographical note

Funding Information:
1CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK; 2Nuffield Department of Population Health, University of Oxford, Oxford OX3 7DQ, UK; 3Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Oxford OX3 7DQ, UK; 4Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 7DU, UK and 5Sussex Cancer Centre, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK

We thank Marcus Green for his expert technical assistance with block sectioning. This work was funded by CRUK Programme Grant C5255/A15935 (to AEK) and an MRC studentship to AKW (MR/K501256/1).

Publisher Copyright:
© 2017 Cancer Research UK.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2017.188

Cite this

@article{8986eff2bc1647ff9245c4fb506376d4,

title = "No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy",

abstract = "Background:The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers.Methods:Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease.Results:We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy.Conclusions:MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.",

author = "Walker, {Alexandra K.} and Christiana Kartsonaki and Elena Collantes and Judith Nicholson and Gilbert, {Duncan C.} and Kiltie, {Anne E.}",

note = "Funding Information: 1CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK; 2Nuffield Department of Population Health, University of Oxford, Oxford OX3 7DQ, UK; 3Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Oxford OX3 7DQ, UK; 4Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 7DU, UK and 5Sussex Cancer Centre, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK We thank Marcus Green for his expert technical assistance with block sectioning. This work was funded by CRUK Programme Grant C5255/A15935 (to AEK) and an MRC studentship to AKW (MR/K501256/1). Publisher Copyright: {\textcopyright} 2017 Cancer Research UK.",

year = "2017",

month = jul,

day = "25",

doi = "10.1038/bjc.2017.188",

language = "English",

volume = "117",

pages = "322--325",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy

AU - Walker, Alexandra K.

AU - Kartsonaki, Christiana

AU - Collantes, Elena

AU - Nicholson, Judith

AU - Gilbert, Duncan C.

AU - Kiltie, Anne E.

N1 - Funding Information: 1CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK; 2Nuffield Department of Population Health, University of Oxford, Oxford OX3 7DQ, UK; 3Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, Oxford OX3 7DQ, UK; 4Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford OX3 7DU, UK and 5Sussex Cancer Centre, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK We thank Marcus Green for his expert technical assistance with block sectioning. This work was funded by CRUK Programme Grant C5255/A15935 (to AEK) and an MRC studentship to AKW (MR/K501256/1). Publisher Copyright: © 2017 Cancer Research UK.

PY - 2017/7/25

Y1 - 2017/7/25

N2 - Background:The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers.Methods:Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease.Results:We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy.Conclusions:MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.

AB - Background:The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemo-radiotherapy when compared with HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers.Methods:Using a previously reported cohort, we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease.Results:We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy.Conclusions:MRE11 has no predictive value in the analysis of relapse-free survival after chemo-radiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour-infiltrating lymphocyte scores. Further investigation into the role of DNA repair proteins in anal cancer is required.

UR - http://www.scopus.com/inward/record.url?scp=85029286086&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.188

DO - 10.1038/bjc.2017.188

M3 - Article

C2 - 28641314

AN - SCOPUS:85029286086

SN - 0007-0920

VL - 117

SP - 322

EP - 325

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3

ER -

No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this